Skip to content

Alumis Inc. ALMS Net Investment in Lease

Net Investment in Lease at other companies

Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.12B+739%
Enterprise value$3.1B+1,238%
P/S371.9×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s net investment in lease?
Alumis Inc. (ALMS) reported net investment in lease of $15.95M in Q1 2026.
How has Alumis Inc.'s net investment in lease changed year-over-year?
Alumis Inc.'s net investment in lease increased by 12.1% year-over-year, from $14.23M to $15.95M.
What is the long-term trend for Alumis Inc.'s net investment in lease?
Over 2 years (2023 to 2025), Alumis Inc.'s net investment in lease has grown at a 15.2% compound annual growth rate (CAGR), from $12.78M to $16.97M.